Chadi Hage Chehade

Huge congratulations to my mentor and friend @neerajaiims on his election to the @ASCO Nominating Committee. A true leader whose humility, vision, and mentorship continue to inspire so many. @OncoAlert brnw.ch/21wYvzE

Delayed genomic testing limits access to life-prolonging cancer treatments. @chadihcmd @huntsmancancer joins @neerajaiims to discuss the utilization of next-generation sequencing in nearly 200,000 patients with common cancers having approved targeted therapies. #WatchNow on UroToday > bit.ly/4fOR7EX

Thrilled for Day 2 of invigorating discussions on prostate and renal cell cancer at #UromigosLive! by @tompowles1 @brian_rini @Uromigos @OncoAlert @urotoday

Excited to be part of @Uromigos LIVE & UnpluggD ‘25! Can’t wait for the lively, engaging, unfiltered, and insightful conversations that make this meeting so special @OncoAlert

Voting for the ASCO election is now open! I am honored to be running as one of the candidates for the @ASCO Nominating Committee seat. Visit asco.org/election to learn more about the candidates and place your vote! Thank you!!

Proud to endorse my mentor and friend @neerajaiims for the @ASCO Nominating Committee! His humility, kindness, unwavering dedication to mentoring young investigators globally & advancing cancer research inspire me every day. A true leader who lifts everyone around him.

Delayed genomic testing limits access to life-prolonging cancer treatments. @chadihcmd @huntsmancancer joins @neerajaiims to discuss the utilization of next-generation sequencing in nearly 200,000 patients with common cancers having approved targeted therapies. #WatchNow on UroToday > bit.ly/4fOR7EX

Thank you Neeraj for reminding us of the importance of accessibility in NGS testing for metastatic prostate cancer. Equity must guide innovation. #IUCS25 @chadihcmd @urologysummit @gbanna74 @ravikanesvaran @OncoAlert @ONCOassist @neerajaiims @PGrivasMDPhD @drenriquegrande @montypal @nataliagandur @alison_tree @ManiamAkash @Ecastromarcos @huntsmancancer

Delayed genomic testing limits access to life-prolonging cancer treatments. @chadihcmd @huntsmancancer joins @neerajaiims to discuss the utilization of next-generation sequencing in nearly 200,000 patients with common cancers having approved targeted therapies. #WatchNow on UroToday > bit.ly/4fOR7EX

Congrats to Dr. Chadi Hage Chehade on presenting at #ASCO25 on the timing and use of tumor next-generation sequencing testing for the 5 most common cancers in the U.S., and receiving the Conquer Cancer Merit Award! Check out his interview with @urotoday: lnkd.in/gJpDJyqk

🌟🌎 #GlobalGUFriday 🧬 PARP inhibitors: from ovarian cancer to a pan-tumor approach — Landmark phase III trials transforming care in HRR-mutated tumors. @chadihcmd @ggebraelmd @nsayeghmd @ziremozay @SWOGadvocate @JenniferLitton @umangtalking @neerajaiims 📌 FDA/EMA approvals based on pivotal data: 🟣 Ovary – SOLO-1/2, PRIMA, PAOLA-1, ARIEL3 (maintenance & 1L combo) 🩷 Breast – OlympiA, EMBRACA (gBRCA early & metastatic) 🟡 Prostate – PROfound, PROpel, MAGNITUDE, TALAPRO-2 (mCRPC) 🟢 Pancreas – POLO (gBRCA mPDAC maintenance) 💡 Mechanism: Exploits DNA repair defects → synthetic lethality 📈 Benefit: OS & PFS gains across tumor types 🔍 Trends: Expanding into combinations (IO, ADCs), early stages, and basket trials 💡 Main messages: 1️⃣ Synthetic lethality is now a validated therapeutic principle across tumor types. 2️⃣ HRR testing (BRCA1/2, ATM, PALB2…) should be integrated into routine work-up. 3️⃣ Maintenance strategies prolong disease control and delay chemo. 4️⃣ Combinations with IO & ADCs may expand benefit beyond BRCA+ disease. 🩺 Clinical implications: ✔ Test early → identify candidates before progression. ✔ Cross-tumor genomic panels are now standard in advanced disease. ✔ Watch for hematologic toxicity, fatigue & GI AEs — require proactive management. @OncoAlert @APCCC #PARPinhibitors #DNArepair #PrecisionOncology #OncoTwitter #Medicalwatch pubmed.ncbi.nlm.nih.gov/39791278/

PARP inhibitors comprise a therapeutic class that targets PARP proteins involved in DNA repair. This #OpenAccess review of PARP inhibitor approvals emphasizes their efficacy across different cancers based on landmark phase 3 clinical trials. 🔗: acsjournals.onlinelibrary.wiley.com/doi/full/10.33…

Feeling Incredible honored to receive the #JQTF award!🌟 Huge thanks to my mentors @PGrivasMDPhD & JWright - Always inspired 💯 Grateful to @BladderCancerUS for advancing research & advocacy. 🙏 Congrats @AmandaMyersMD @Anto_cigliola @alexzhuDO @DrAndrewKatims #BCANTT25 👏

Join us in congratulating the following members on earning the Fellows of ASCO (FASCO) distinction last quarter! We are grateful for their extraordinary volunteer service, dedication, and commitment to ASCO. Learn more about FASCO distinction: brnw.ch/21wUiVu

A very informative and detailed discussion on practice changing data and trial updates in bladder cancer by @PGrivasMDPhD #BestOfASCO 2025 in Boise! education.binaytara.org/content/best-a…

Just came online in @TheLancet 👉Our two papers on improved OS with Enzalutamide + Talazoparib in mCRPC #ProstateCancer in all-comer & HRRm patients (Median OS and HRs👇). Weblinks to the papers👉 bit.ly/4lXkLtB and bit.ly/4nNIyOh @PCFnews @urotoday @OncoAlert

Real-world data show that only 30% to 40% of patients with the most common cancers receive NGS testing. 🗨️ “The ultimate goal would be for all patients to receive NGS testing earlier in their disease course," - @chadihcmd of @huntsmancancer told Healio. bit.ly/4lzH2gU

Metformin did not boost survival in metastatic hormone-sensitive prostate cancer. It did ease ADT’s metabolic side effects. Not a game-changer, but still some hope for patient quality of life. #Oncology With very nice editorial by @ggebraelmd @chadihcmd and @neerajaiims @TheLancetOncol @APCCC_Lugano @Silke_Gillessen @Prof_Nick_James @AlisonBirtle @scserendipity1 @AttardLab @drdjmath @mattsydes doi.org/10.1016/S1470-… doi.org/10.1016/S1470-…

✏️@neerajaiims, @chadihcmd, and Georges Gebrael discuss the STAMPEDE trial in their linked comment See here: thelancet.com/journals/lanon…

@PGrivasMDPhD @eaonc @PrECOGonc @NaomiHaas5 @MonikaJoshimd @JCensits @HutchPresident @nicoleflemingmd @Dr_AmerZeidan @BrainTumorDoc @shilpaonc @OncoAlert @TiansterZhang Congratulations Dr. Grivas!

So honored to receive this prestigious award by @eaonc kudos to all investigators/staff who work hard to conduct trials globally! @PrECOGonc @NaomiHaas5 @MonikaJoshimd @JCensits @HutchPresident @nicoleflemingmd @Dr_AmerZeidan @BrainTumorDoc @shilpaonc @OncoAlert @TiansterZhang